AstraZeneca Plc said its experimental hypertension pill reduced blood pressure by more than twice as much as standard treatment in a large late-stage study, bolstering its chances of competing in a crowded field.
The highest dose of the daily baxdrostat pill cut blood pressure by an average 15.7 mm Hg, or millimeters of mercury, when added to other hypertension medicines over 12 weeks, according to the study presented Saturday to the European Society of Cardiology meeting in Madrid. Patients who got a placebo on top of other hypertension drugs saw their blood pressure fall 5.8 mm Hg.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.